Nasal sinus cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:52 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Nasal sinus cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of low-dose radiation therapy combined with paclitaxel and carboplatin in patients with advanced throat and larynx cancer https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-low-dose-radiochemotherapy-with-carboplatin-and-paclitaxel-for-patients-with-advanced-throat-and-larynx-cancer/ Wed, 29 Apr 2026 15:02:24 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-low-dose-radiochemotherapy-with-carboplatin-and-paclitaxel-for-patients-with-advanced-throat-and-larynx-cancer/ This clinical trial focuses on patients with advanced throat and larynx cancer. The study evaluates a treatment approach called induction radiochemotherapy that uses low doses of ionizing radiation combined with chemotherapy medications. The chemotherapy drugs used in this study are paclitaxel and carboplatin, which are given through an intravenous injection directly into the bloodstream.

The purpose of this research is to determine how effective and well-tolerated this combined treatment approach is for patients with advanced throat and larynx cancer. The treatment involves receiving both chemotherapy medications along with low-dose radiation therapy. During the study, patients will receive treatment over a period of up to 37 days.

The study will monitor how patients respond to the treatment by examining the cancer’s response, checking for any spread of the disease, and tracking overall patient survival. The research will also look at how low doses of radiation affect the body at both molecular and biochemical levels. Throughout the treatment period, doctors will carefully watch for and record any side effects that patients may experience.

]]> Study of Pembrolizumab and Chemotherapy for Patients with Locally Advanced Sinonasal Carcinoma https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-chemotherapy-for-patients-with-locally-advanced-sinonasal-carcinoma/ Wed, 29 Apr 2026 14:26:23 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-chemotherapy-for-patients-with-locally-advanced-sinonasal-carcinoma/ This clinical trial is focused on studying a type of cancer called locally advanced sinonasal carcinoma, which affects the nasal cavity and sinuses. The study will explore the use of a medication called pembrolizumab, also known by its code name MK-3475, in combination with chemotherapy. Pembrolizumab is a type of treatment that helps the immune system fight cancer cells. The purpose of the study is to evaluate the safety and effectiveness of this combination as a treatment before surgery, known as neoadjuvant therapy, for patients with this type of cancer.

Participants in the study will receive pembrolizumab along with chemotherapy. The treatment is given as a solution for infusion, which means it is administered directly into the bloodstream through a vein. The study will last for a period of up to 48 weeks, during which the effects of the treatment will be closely monitored. Some participants may receive a placebo, which is a substance with no active medication, to compare the results with those receiving the actual treatment.

The main goal is to observe how well the cancer responds to the treatment, looking for signs of complete or partial remission, which means the cancer shrinks or disappears. This study aims to provide valuable information on whether pembrolizumab combined with chemotherapy can be a safe and effective option for treating locally advanced sinonasal carcinoma before surgery.

]]>